Business context and reporting period
Iovance Biotherapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2021. The company is a clinical-stage biotechnology business developing patient-specific tumor-infiltrating lymphocyte (TIL) cell therapies. Its lead candidates are lifileucel for metastatic melanoma and cervical cancer, and LN-145 for non-small cell lung cancer (NSCLC). The company had no approved products and generated no operating revenue.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $259.0 million | $201.7 million |
| General and administrative expense | $83.7 million | $60.2 million |
| Net loss | $342.3 million | $259.6 million |
| Net loss per share, basic and diluted | $2.23 | $1.88 |
| Cash used in operating activities | $227.9 million | $205.1 million |
Liquidity: At year-end, cash, cash equivalents, investments and restricted cash totaled $602.1 million, including $6.1 million of restricted cash. Management said available capital was expected to fund planned operating expenses and capital expenditures for at least 12 months from the filing date. The company reported total assets of $777.3 million and stockholders’ equity of $621.7 million.
Debt and obligations: The balance sheet included a $1.0 million long-term, unsecured, non-interest-bearing job-creation loan. Operating lease liabilities were $70.5 million; disclosed future facility lease payments totaled $129.7 million before present-value adjustments and tenant-improvement reimbursement. No off-balance-sheet arrangements were reported. Gross margin is not meaningful because the company had no product revenue.
Material changes versus the prior comparable period
- Net loss increased $82.7 million, or 32%, from 2020, reflecting expanded research and development, clinical activity and corporate infrastructure.
- R&D expense rose 28%, primarily from higher staffing and stock compensation, iCTC and headquarters costs, and clinical-trial spending. G&A expense rose 39%, driven by staffing, stock compensation, insurance, intellectual-property and infrastructure costs.
- Operating cash use increased $22.8 million to $227.9 million. Financing provided $239.3 million, including $203.2 million net proceeds from at-the-market stock sales and $33.5 million from option exercises. Shares outstanding increased to 157.0 million from 146.9 million at year-end 2020.
- The company placed $62.4 million of iCTC assets into service and reported its first internally manufactured clinical batch of LN-145. It also expanded its new San Carlos headquarters lease.
Outlook, risks and unusual items
- Management expected to submit a BLA for lifileucel in metastatic melanoma in the first half of 2022. FDA feedback on potency assays had delayed the filing; assay development and validation remained ongoing, and an independent review of Cohort 4 responses was still required. The filing’s text does not provide a clear final IRC-read Cohort 4 efficacy result.
- For cervical cancer, management planned to pursue a potential BLA strategy after further FDA discussions, in light of changes to the treatment landscape. LN-145’s NSCLC study was enrolling, with enrollment expected to continue through 2022. A first clinical study of genetically modified TIL candidate IOV-4001 was also expected in 2022.
- Selected clinical results were preliminary and from small or single-arm cohorts. In melanoma Cohort 2, lifileucel had a reported 36% objective response rate and 80% disease-control rate in 66 patients; median duration of response had not been reached after 33.1 months’ median follow-up. The filing reports differing complete-response counts in separate passages, so that figure should be checked against the underlying study disclosure.
- Management cited ongoing losses, substantial development and manufacturing costs, clinical and regulatory uncertainty, manufacturing scale-up and assay-validation risks, reliance on contract manufacturers and suppliers, competition, reimbursement uncertainty, and potential dilution from future equity financing. The company expected no significant product or licensing revenue in the next 12 months and anticipated higher spending in 2022 and beyond, including approximately $10–11 million of capital expenditures over the next 12 months.
- The company said COVID-19 had not materially affected 2021 liquidity or results and had not significantly affected trial enrollment to date, but future impacts remained uncertain. It reported a $1.2 billion accumulated deficit and expected continued losses.
- Legal matters included a derivative action concerning director compensation and two Solomon-related lawsuits; management said the loss range was not estimable for the identified matters. A $1.0 million Pennsylvania job-creation loan may be forgiven based on employment levels, but the company did not consider forgiveness reasonably assured at year-end.
- The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting at December 31, 2021. The auditor identified accrued clinical development costs as a critical audit matter.
Most important facts for investors to verify
- Whether FDA potency-assay requirements were resolved and whether the melanoma BLA was submitted, accepted and ultimately approved on the anticipated timeline.
- Final independent-review efficacy, safety and follow-up results for melanoma Cohort 4, and consistency of those results with earlier investigator-assessed data.
- Cash burn, financing needs and dilution, particularly as clinical development, commercial readiness and manufacturing costs increase.
- iCTC commercial readiness, manufacturing capacity, product consistency, cost per treatment and dependence on external manufacturers.
- Progress and registration plans for cervical cancer and NSCLC, alongside changes in standard of care, competition and reimbursement prospects.
- Developments in the disclosed litigation and any material updates to the company’s CEO leadership transition.